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Abstract
Background: Cryptococcal meningitis is a leading cause of death among HIV-infected individuals in sub-Saharan
Africa. Recent developments include the availability of intravenous fluconazole, cryptococcal antigen assays and
new data to support fluconazole pre-emptive treatment. In this study, we describe the impact of screening HIV-
positive adult inpatients with serum cryptococcal antigen (CRAG) at a Tanzanian referral hospital.
Methods: All adults admitted to the medical ward of Bugando Medical Centre are counseled and tested for HIV. In
this prospective cohort study, we consecutively enrolled HIV-positive patients admitted between September 2009
and January 2010. All patients were interviewed, examined and screened with serum CRAG. Patients with positive
serum CRAG or signs of meningitis underwent lumbar puncture. Patients were managed according to standard
World Health Organization treatment guidelines. Discharge diagnoses and in-hospital mortality were recorded.
Results: Of 333 HIV-infected adults enrolled in our study, 15 (4.4%) had confirmed cryptococcal meningitis and 10
of these 15 (66%) died. All patients with cryptococcal meningitis had at least two of four classic symptoms and
signs of meningitis: fever, headache, neck stiffness and altered mental status. Cryptococcal meningitis accounted
for a quarter of all in-hospital deaths.
Conclusions: Despite screening of all HIV-positive adult inpatients with the serum CRAG at the time of admission
and prompt treatment with high-dose intravenous fluconazole in those with confirmed cryptococcal meningitis,
the in-hospital mortality rate remained unacceptably high. Improved strategies for earlier diagnosis and treatment
of HIV, implementation of fluconazole pre-emptive treatment for high-risk patients and acquisition of better
resources for treatment of cryptococcal meningitis are needed.
Background
Cryptococcal meningitis is one of the most common
and severe opportunistic infections among people
infected with HIV: there are an estimated 720, 000 cases
and 500, 000 deaths per year in sub-Saharan Africa
alone [1,2]. In community-based studies, cryptococcal
meningitis accounts for between 13% and 44% of all
deaths of HIV-infected individuals [3-5]. Despite the roll
out of antiretroviral therapy (ART), the incidence of
cryptococcal meningitis remains at about 3% per year
among HIV-infected individuals in sub-Saharan Africa
[2,6].
Although advances in the treatment of cryptococcal
meningitis have decreased mortality in high-income coun-
tries, mortality due to cryptococcal meningitis in middle-
and low-income countries remains high [2,7,8]. The mor-
tality rate from cryptococcal meningitis in sub-Saharan
Africa has been estimated at 70% compared with 55% in
other low- and middle-income countries and 20% in high-
income countries [2]. This higher mortality is thought to
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coccal meningitis, as well as the inaccessibility of first-line
treatment with combination amphotericin/flucytosine
induction chemotherapy and intensive intracranial pres-
sure management [8,9].
Our referral hospital in northwestern Tanzania has
recently obtained two tools in an effort to improve man-
agement of cryptococcal meningitis: intravenous flucona-
zole and the cryptococcal antigen assay. High-dose
fluconazole (800-1200 mg daily) has been recommended
as an alternative, though suboptimal, induction therapy for
regions where amphotericin and/or flucytosine are not
available [8,10-12]. The serum cryptococcal antigen assay
is a sensitive and specific screening tool that has been stu-
died in several outpatient HIV-infected cohorts in sub-
Saharan Africa, where the prevalence has been 7% to 8%
[13,14]. The prevalence of cryptococcal antigenemia
among HIV-positive inpatients in sub-Saharan Africa has
not been reported.
In our hospital, we have been tracking the diagnosis
and outcomes of cryptococcal meningitis since January
2010. In the nine months before the initiation of this
study, between January and August 2010, there were a
total of 47 cases of cryptococcal meningitis admitted to
our hospital (5.2 cases per month) and 34 of 47 (72.3%)
of these patients died in hospital despite treatment with
high-dose intravenous fluconazole. Clinicians felt that
delayed diagnosis, often one to two weeks after the day of
admission, may have been contributing to this mortality
and that earlier diagnosis and earlier initiation of IV flu-
conazole, closer to the time of admission, may improve
the outcome of these patients.
Therefore, in this study we screened a population of
HIV-positive adult inpatients with the serum cryptococ-
cal antigen in order to determine if universal screening
at the time of admission could lead to earlier diagnosis
and treatment of cryptococcal meningitis and to better
in-hospital outcomes. We also describe the prevalence,
clinical characteristics and in-hospital mortality of cryp-
tococcal meningitis treated with high-dose intravenous
fluconazole in the ART era.
Methods
Trial design and study participants
This prospective cohort study was completed between
September 2009 and January 2010 in the inpatient medi-
cal wards of Bugando Medical Centre (BMC). BMC is a
tertiary referral hospital that serves the Lake Victoria
region of northwestern Tanzania (population of about
13 million) and is located in the city of Mwanza. On
average, 10 adult patients are admitted to our medical
wards daily. Approximately 25% are HIV positive. By
hospital policy, all patients who are not known to be
HIV positive undergo counselling for HIV at the time of
admission and are tested for HIV if they consent.
All HIV-positive adults admitted to the medical ward
during the study period, who met the enrolment criteria
and signed informed consent, were enrolled in the study.
Patients younger than 18 years, those who had previously
been diagnosed with cryptococcal meningitis and those
who had received pre-emptive treatment for cryptococcal
meningitis were excluded.
Data collection
Patients were interviewed and examined within 24 hours
of admission using a structured questionnaire to collect
demographic information, clinical symptoms and physical
signs. For all HIV-infected patients, 5 milliliters of blood
was drawn for serum cryptococcal antigen at the time of
enrolment, as well as for CD4 cell count if this had not
been documented within the last three months. Lumbar
puncture was performed on all patients with signs of clini-
cal meningitis or positive serum cryptococcal antigen.
Cerebrospinal fluid (CSF) was sent for both cryptococcal
antigen and India ink staining. The cryptococcal antigen
assay is a World Health Organization (WHO) approved
test that was already being used routinely for diagnosis of
cryptococcal meningitis at BMC before the beginning of
this study. The results of all tests were reported immedi-
ately to the responsible clinicians. Discharge diagnoses
and outcome were recorded for all patients.
The treatment of cryptococcal meningitis followed the
recommendations of WHO and the Tanzanian Ministry
of Health [15-17]. Pre-emptive treatment for cryptococ-
cal meningitis is not yet recommended in Tanzania and
none of our patients had received pre-emptive treatment.
All patients with cryptococcal meningitis in this study
were treated with two weeks of intravenous fluconazole
(1200 mg daily, intensive phase) followed by eight weeks
of oral fluconazole (400 mg daily, maintenance phase).
Patients whose physicians judged their CSF drip rate to
be increased at the time of the initial lumbar puncture
received serial lumbar punctures for reduction of intra-
cranial pressure. Manometers to quantify CSF pressure
were not available in our hospital.
Laboratory analyses
Serum and CSF cryptococcal antigen assay was per-
formed using the latex agglutination test kit (CALAS,
Meridian Bioscience Europe, Nice, France) following
manufacturer instructions. This assay includes a pronase
and has been shown to have a sensitivity of 93% to 100%
and a specificity of 96% to 98% [18]. Serial dilutions were
performed to determine quantitative titers. CSF crypto-
coccal antigen assays with a titre of ≥1:4 were defined as
positive. Due to limited supply of reagent, serum CRAG
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were only diluted to 1:32. CSF was also examined with
India ink stain (Pelikan, Hanover, Germany). CD4 counts
were determined using FACSCalibur Flow Cytometry
(BD, San Jose, USA). Fungal culture was not performed.
Definitions
Cryptococcal meningitis was defined as a positive cryp-
tococcal antigen and/or India ink test in the CSF. Disse-
minated cutaneous cryptococcosis was defined as a
positive cryptococcal antigen with consistent skin lesions
since our hospital was not equipped for performance of
confirmatory skin biopsies. The diagnoses of tuberculo-
sis, non-cryptococcal meningitis, chronic diarrhea, pneu-
mocystis pneumonia and other opportunistic conditions
were made according to WHO clinical definitions
[15,16].
Data analysis
Data were entered into Microsoft Excel 2007 and were
analyzed using SAS (Cary, North Carolina). Categorical
variables were summarized by frequency and percentage,
and continuous variables were summarized by median
and interquartile range. Categorical variables were com-
pared using the Chi-squared (c2) or Fisher’s Exact tests
and continuous variables were compared using the Log
Rank-Sum test. All variables with significant associations
to cryptococcal meningitis on univariate analysis were
subjected to multivariate analysis. All statistical testing
was done at the 95% confidence interval, and we consid-
ered a p value < 0.05 to be statistically significant.
Ethical issues
Ethical approval was obtained from the BMC and Weill
Cornell Medical College IRBs and a written informed
consent was obtained from each patient or their surro-
gate for unconscious patients. Due to limited ability to
communicate with family members who did not visit the
hospital, surrogates were chosen from among the people
who cared for the unconscious patient in the hospital.
Primary relatives and/or spouses were preferred and used
in almost all cases. HIV status was not revealed to surro-
gates who were not previously aware of the HIV status of
the patient.
Results
Enrolment
Between 1 September 2009 and 9 January 2010, a total of
1595 adults were admitted to the BMC medical wards.
Of these, 243 (15.2%) were known to be HIV positive at
the time of admission and 142 (8.9%) were found to be
HIV positive after voluntary counseling and testing. Thus
a total of 385 HIV-positive adults were admitted to BMC
during the study period, and 333 (86.5%) were enrolled.
Screening, exclusion and enrolment statistics are sum-
marized in Figure 1.
Patient characteristics
Among the 333 adult HIV-positive patients enrolled in
the study, the median age was 36 years (IQR 18-54
years) and 53.8% of the patients were women. As noted,
243 (73.0%) were aware of their HIV status on admis-
sion. The median CD4 count was 209 cells/mm
3 (IQR
87-378) and 93 patients (27.9%) had CD4 counts of less
than 100 cells/mm
3. Among the patients enrolled, 164
(49.3%) were already on ART, and the majority of these
(70.7%) had been on ART for 180 days or more.
Screening for cryptococcal meningitis
Of the 333 HIV-infected adult inpatients enrolled in this
study, 17 (5.1%) had a positive serum cryptococcal anti-
gen. Among these 17 patients, the median CD4 count
was 68 cells/mm
3 (IQR 41-87, range 1-102 cells/mm
3).
Fifteen of these 17 patients (4.4% of all study patients)
had confirmed cryptococcal meningitis with both a posi-
tive CSF cryptococcal antigen and a positive India ink
test. The remaining two patients with positive serum but
negative CSF cryptococcal antigen and India ink had skin
lesions that were consistent with disseminated cutaneous
cryptococcosis. No patient with a positive CSF cryptococ-
cal antigen or India ink had a negative serum cryptococ-
cal antigen.
Among the 15 patients with confirmed cryptococcal
meningitis, the median age was 41 years (IQR 32-47) and
53.3% were women. Of these, nine (60%) knew their HIV
status at the time of admission and six (40%) were on
ART. The median CD4 count of patients with cryptococ-
cal meningitis was 68 cells/mm
3 (IQR 54-87) and 14
(93.3%) had CD4 counts below 100 cells/mm
3 (overall
range 1-102 cells/mm
3). The prevalence of cryptococcal
meningitis was 14 of 93 (15.0%) patients with CD4
counts below 100 cells/mm
3, six of 90 (6.7%) with a new
diagnosis of HIV, and five of 48 (10.4%) who had been on
ART for less than three months. The baseline character-
istics of our cohort are described in Table 1, divided by
diagnosis of cryptococcal meningitis or other diagnosis.
Clinical characteristics of cryptococcal meningitis
The univariate analysis for baseline clinical characteristics
that predicted the diagnosis of cryptococcal meningitis is
s h o w ni nT a b l e1 .S i g n i f i c a n tp r e d i c t o r sb yu n i v a r i a t e
analysis included CD4 counts of less than 100 cells/mm
3,
less than 180 days on ART, headache, fever (> 37.5°C),
altered mental status (Glascow Coma Scale ≤ 14) and
neck stiffness. By multivariate analysis, risk factors for
cryptococcal meningitis included: CD4 counts of less
than 100 cells/mm
3 (OR 28.0, 95% CI 2.9-272.0), altered
mental status (OR 25.3, 95% CI 5.1-126.2), neck stiffness
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1.1- 29.1). All patients had increased intracranial pressure
as measured by the drip rate at the time of initial, diag-
nostic lumbar puncture, and all patients underwent serial
drainage of 10-15 mL of CSF on hospital days 0, 3 and 7
according to our hospital’s protocol. All patients with
cryptococcal meningitis had at least two of the four clas-
sic symptoms and signs of meningitis (fever, headache,
altered mental status and neck stiffness).
Outcomes
Of the 333 HIV-infected adult inpatients in our study,
38 (11.4%) died in hospital. Of the 15 with cryptococcal
meningitis, 10 died. Cryptococcal meningitis accounted
for 26.3% (10 of 38) of all deaths, more than any other
single diagnosis. The discharge diagnoses, in-hospital
mortality rates and contribution to overall mortality are
summarized in Table 2.
Mortality was associated with higher serum and CSF
cryptococcal antigen titers. Of the 11 patients with CSF
antigen titre ≥ 1:32 or serum titre ≥ 1:64 mortality was 10/
11, as compared with 0/4 for those with lower titres (p =
0.004). Serum and CSF cryptococcal antigen titres were
the only statistically significant predictors of death among
patients with cryptococcal meningitis in our cohort.
Discussion
Of the 333 HIV-infected adults consecutively admitted to
our Tanzanian hospital during the ART era and screened
with the serum cryptococcal antigen, 15 (4.5%) had con-
firmed cryptococcal meningitis and 10 of 15 died in hospi-
tal despite high-dose intravenous fluconazole initiated
within 24 hours of admission. All patients with cryptococ-
cal meningitis had typical symptoms. One-quarter of all
deaths in this cohort were due to cryptococcal meningitis.
The prevalence of cryptococcal meningitis among HIV-
infected adult inpatients may be decreasing with earlier
HIV diagnosis and increasing ART use. We observed a
lower prevalence of cryptococcal meningitis (4.5%) than
prior studies. Another study conducted at a referral hospi-
tal (Kilimanjaro Christian Medical Center) in central Tan-
zania reported a prevalence of cryptococcal meningitis of
40 out of 149 (26.8%) HIV-infected adults admitted with a
chief complaint of either headache or altered mental status
[19]. Of 113 patients with either headache or altered men-
tal status in our cohort, 15 (13.3%) had cryptococcal
meningitis. The lower prevalence of cryptococcal meningi-
tis in our population is likely due to higher median CD4
c o u n t( 2 0 9v s .1 4 7c e l l s / m m
3 a tK C M C )a sw e l la st h e
inclusion of more patients on ART (50% vs. 22% at
KCMC) [20].
1352unknownHIVstatus
duringadmission
243knownHIV
positive
7refusedHIV
testing
1345consentedtoHIV
testing
1203HIV
negative
142newHIV
diagnoses
Outof385HIVͲpositivepatients’admissions,52patientswereexcluded:
Ͳ 40were<18yearsold
Ͳ 8weredischargedbeforeenrolment
Ͳ 4diedbeforeenrolment
333Enrolled
1595totaladmissionsduring
thestudyperiod
Figure 1 Screening and enrollment. Screening and enrolment statistics for 1595 adults admitted to the medical wards of Bugando Medical
Centre in Mwanza, Tanzania between 1 September 2009 and 9 January 2010.
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among the HIV-positive adult inpatients in our study
and the high rates of ART use (50% in our cohort),
cryptococcal meningitis still accounted for 26% of all in-
hospital AIDS deaths. These findings are consistent with
reports from community-based, HIV-infected adult
cohorts in sub-Saharan Africa during both the pre-ART
and post-ART eras where 13% to 44% of deaths were
attributed to this infection [2-6]. The in-hospital mortal-
ity rates for cryptococcal meningitis also remain high
despite recent improvements in access to high-dose
intravenous fluconazole and cryptococcal antigen testing
[8,9,21]. Although patients were diagnosed and initiated
on fluconazole within 24 hours of presentation to our
hospital, the mortality rate remained close to 70%,
comparable with rates reported by others in sub-
Saharan Africa [2,10,11].
The 66% in-hospital mortality rate seen in our patients
with cryptococcal meningitis is very high compared with
20% acute mortality rates seen in high-income countries
where amphotericin-based induction therapy, intensive
intracranial pressure management and earlier presenta-
tion are the norm [2]. Intravenous fluconazole is known
to be inferior to combination induction therapy with
amphotericin/flucytosine [9,11]. Also, our hospital does
not have the equipment necessary for intensive intracra-
nial pressure management, which has been associated
with decreased mortality in cryptococcal meningitis and
is recommended by the Infectious Diseases Society of
America [12,22]. One possible benefit of the early,
Table 1 Baseline characteristics of HIV-infected adults admitted to Bugando Medical Centre divided by diagnosis
Cryptococcal meningitis
(n = 15)
Other diagnoses
(n = 318)
p value
Age (years)
18-30 3 (20.0%) 85 (26.7%) 0.77
31-40 4 (26.7%) 118 (37.1%) 0.59
41-50 5 (33.3%) 70 (22.01%) 0.34
51-60 2 (13.3%) 30 (9.4%) 0.65
> 60 1 (6.7%) 15 (4.7%) 0.53
Median (IQR) 41.0 (32-47) 36.0 (30-44) 0.29
Gender
Male 7 (46.7%) 147 (46.2%) 1
Female 8 (53.3%) 171 (53.8%)
CD4 profile (cells/mm
3)
< 100 14 (93.3%) 79 (24.8%) < 0.0001
100-200 1 (6.7%) 61 (19.2%) 0.32
> 200 0 (0%) 178 (56.0%) < 0.0001
Median (IQR) 68.0 (54-87) 228.0 (101-379) 0.0006
HIV status on admission
New diagnosis 6(40%) 84(26.42%) 0.25
Known 9(60%) 234(73.58%)
Days on antiretroviral therapy
Never 8 (53.3%) 162 (50.9%) 1
< 180 5 (33.3%) 43 (13.5%) 0.05
> 180 2 (13.3%) 113 (35.5%) 0.097
Median (IQR) 92 (61-214) 293 (147-589) 0.003
Symptoms/signs on admission
Headache 11 (73.3%) 87 (27.6%) 0.0004
Fever (T > 37.5°C) 14 (93.3%) 204 (64.2%) 0.02
Altered mental status (GCS ≤14) 10 (66.7%) 19 (6.0%) < 0.0001
Neck stiffness 9 (60%) 22 (6.9%) 0.0001
None of the above 0 97 (30.5%)
≥ 1 of the above 15 (100%) 221 (69.5%) 0.007
≥ 2 of the above 15 (100%) 108 (33.9%) < 0.0001
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that early, aggressive, empiric ICP management could be
initiated on CRAG-positive patients according to the
protocol recommended by Bicanic et al [23]. Finally,
patients in our setting often present for medical care
late in the course of their illness [24,25].
Universal screening of symptomatic, HIV-infected adult
inpatients with a serum cryptococcal antigen does not
seem to be necessary. All of the patients with cryptococcal
meningitis in our cohort had at least two of the four clas-
sic symptoms and signs of meningitis: headache, fever,
neck stiffness and altered mental status. Predictors of
cryptococcal meningitis by multivariate analysis included
CD4 T cell counts of under 100 cells/mm
3, altered mental
status (GCS ≤ 14), fever (temperature > 37.5C) and neck
stiffness, consistent with other studies [3,19,26]. Among
adult HIV-infected inpatients, targeted serum CRAG
screening for patients with symptoms and signs of menin-
gitis and (if known) a CD4 T cell count of less than 200
cells/mm
3 may be a reasonable approach in hospitals in
sub-Saharan Africa.
A growing body of research suggests that an even bet-
ter use of the serum CRAG would be as a screening
tool among asymptomatic HIV-infected adults, particu-
larly before the initiation of ART in patients with CD4
counts under 100 cells/mm
3 [13,27]. In patients found
to have asymptomatic antigenemia, pre-emptive treat-
ment with fluconazole has been shown to reduce mor-
tality [14,28]. One of the limitations of our study is that
we could not detect patients with asymptomatic antige-
nemia since we only screened symptomatic, hospitalized
patients.
Of the 15 cases of cryptococcal meningitis in our
study, five (33%) occurred in adults who had been on
ART for less than three months and qualify as “ART-
associated cryptococcosis” according to new consensus
definitions [29]. We suspect that some if not all of these
cases represent unmasking cryptococcal meningitis
Immune Reconstitution Inflammatory Syndrome (IRIS),
but cannot definitively make this diagnosis due to
absence of baseline cryptococcal investigations in our
patients. This is a limitation of our study.
Based on these study results, our hospital has been
able to preserve resources by targeting CRAG testing
among inpatients to those with concerning symptoms
and CD4 counts under 200 cells/mm
3. Our hospital has
also prioritized the pursuit of other measures to reduce
mortality due to cryptococcal meningitis, including
improved strategies for earlier diagnosis and treatment
of HIV, implementation of fluconazole pre-emptive
treatment protocols for high-risk patients, and acquisi-
tion of better resources for treatment of cryptococcal
meningitis.
Conclusions
This study shows how, despite the roll out of ART and
the increased availability of fluconazole and cryptococcal
antigen assays, cryptococcal meningitis still accounted
for a quarter of the deaths of HIV-infected adult inpati-
ents in sub-Saharan Africa. Patients with cryptococcal
meningitis presented with typical symptoms, and univer-
sal screening with a serum cryptococcal antigen assay at
the time of admission did not seem to improve diagnosis
rates compared with traditional, symptom and CD4
count guided testing. Despite immediate treatment with
high-dose intravenous fluconazole, two out of three
patients died in hospital. These findings point to the
urgent need for better strategies and tools for the
Table 2 Discharge diagnoses and in-hospital mortality of HIV-infected adults admitted to Bugando Medical Centre
Diagnosis Frequency Mortality rate % of overall
mortality
Malaria 53/333 (15.9%) 1/53 (1.9%) 1/38 (2.6%)
Tuberculosis 36/333 (10.8%) 1/36 (2.8%) 1/38 (2.6%)
Non-cryptococcal meningitis 31/333 (9.3%) 9/31 (29%) 9/38 (23.7%)
Chronic diarrhea 25/333 (7.5%) 1/25 (4%) 1/38(2.6%)
Bacterial pneumonia 21/333 (6.3%) 1/21 (4.8%) 1/38 (2.6%)
Anemia 11/333 (3.3%) 1/11 (9.1%) 1/38 (2.6%)
Cryptococcal meningitis 15/333 (4.5%) 10/15 (66.7%) 10/38 (26.3%)
Pneumocystis pneumonia 14/333 (4.2%) 3/14 (21.4%) 3/38 (7.9%)
Schistosomiasis 13/333 (3.9%) 2/13 (15.4%) 2/38 (5.3%)
Acute diarrhea 11/333 (3.3%) 0 0
Other diagnoses (deaths listed in parentheses): Esophageal candidiasis 9 (0), Urinary tract infections 9 (0), Kaposi’s sarcoma 8 (0), Peripheral neuropathy 8 (0),
Peptic ulcer diseases 5 (0), Spontaneous bacteria peritonitis 7 (0), Deep vein thrombosis 5 (0), Abscesses 5 (1), Pleural effusion 5 (0), Hypertension 4 (0), Wasting
syndrome 3 (1), HIV-associated nephropathy 3 (0), Encephalopathy 3(0), Diabetic mellitus 2 (0), Skin cryptococcal infection 2 (0), Peripartum cardiomyopathy 2 (0),
Stroke 2 (1), Viral hepatitis 2 (0), Herpes zoster 1 (0), Hodgkin’s lymphoma 1 (1), Aspiration pneumonia 1 (0), Dysentery 4 (1), Post-abortal sepsis 1 (1), Cellulitis 1
(0), Cerebral toxoplasmosis 1 (0), Osteomyelitis 1 (0), Rheumatoid arthritis 1 (0), Bilateral renal tumor 1 (1), Stevens Johnson syndrome 1 (0), Genital warts 1 (0),
Spontaneous pneumothorax 1 (1), Transverse myelitis 1 (0), Empyema thoracic 1 (1), Pericardial effusion 1 (0)
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sub-Saharan Africa.
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